

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method for producing a stable adhesion cell lines-line of mammalian neural precursor cells *in vitro*, comprising the steps of:

- a) preparing an adhesion culture of neural precursor cells in a serum-free medium;
- b) ~~culturing the neural precursor cells in the presence of~~ including a first mitogen; ~~wherein said first mitogen is selected from the group consisting of aFGF, bFGF, EGF, TGF α and combinations thereof;~~
- c) introducing a c-myc construct into ~~the~~ a cell cells of the adhesion culture in serum-free medium including the first mitogen,

wherein the c-myc construct is comprised of a c-myc cDNA fused with at least one element selected from the group consisting of DNA for a ligand binding domain for an estrogen receptor, an androgen receptor, a progesterone receptor, a glucocorticoid receptor, a thyroid hormone receptor, a retinoid receptor, and an ecdysone receptor; and

- d) ~~further~~ culturing the cells including the c-myc construct in a medium containing the first mitogen and a second mitogen,

wherein said second mitogen is selected from the group consisting of aFGF, bFGF, EGF, TGF α , serum and combinations thereof, with the proviso that the second mitogen is other than the first mitogen,

wherein said medium containing the first mitogen and the second mitogen further comprises a myc-activating chemical selected from the group consisting of β -estradiol, RU38486, dexamethasone, thyroid hormones, retinoids, and ecdysone.

Claims 2-3 (canceled).

Claim 4 (original): The method of claim 1, wherein the mammalian neural precursor cells are derived from a human.

Claim 5 (original): The method of claim 1, wherein the mammalian neural precursor cells are derived from an *in vitro* culture of pluripotent embryonic stem cells.

Claims 6-11 (canceled).

Claim 12 (currently amended): A method for producing a stable adhesion clonal cell ~~lines~~ line of mammalian neural precursor cells *in vitro*, comprising the steps of:

- a) preparing an adhesion culture of neural precursor cells in a serum-free medium;
- b) ~~culturing the neural precursor cells in the presence of~~ including a first mitogen, ~~wherein said first mitogen is selected from the group consisting of aFGF, bFGF, EGF, TGF α and combinations thereof;~~
- c) introducing a c-myc construct and a selectable marker into ~~the cells~~ a cell of the adhesion culture in serum-free medium including the first mitogen,

wherein the c-myc construct is comprised of a c-myc cDNA fused with at least one element selected from the group consisting of DNA for a ligand binding domain for an estrogen receptor, an androgen receptor, a progesterone receptor, a glucocorticoid receptor, a thyroid hormone receptor, a retinoid receptor, and an ecdysone receptor;

- d) ~~further~~ culturing the cells including the c-myc construct in a medium containing the first mitogen and a second mitogen, wherein said second mitogen is selected from the group consisting of aFGF, bFGF, EGF, TGF α and combinations thereof, with the proviso that the second mitogen is other than the first mitogen,

wherein said medium containing the first mitogen and the second mitogen further comprises a myc-activating chemical selected from the group consisting of β -estradiol, RU38486, dexamethasone, thyroid hormones, retinoids, and ecdysone; and

- e) collecting c-myc treated cells and co-culturing them with feeder cells free of the selectable marker and capable of supporting survival of the c-myc treated cells in a medium containing the first mitogen and the second mitogen, with the proviso that the second mitogen is other than the first mitogen.

Claims 13-14 (canceled).

Claim 15 (original): The method of claim 12, wherein the mammalian neural precursor cells are derived from a human.

Claim 16 (original): The method of claim 12, wherein the mammalian neural precursor cells are derived from an *in vitro* culture of pluripotent embryonic stem cells.

Claims 17-22 (canceled).